The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: Analysis of NRG RTOG 0524 and 0712.
 
Matthew Pierre Deek
No Relationships to Disclose
 
Amol Shetty
No Relationships to Disclose
 
Yang Song
No Relationships to Disclose
 
Jason A. Efstathiou
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Boston Scientific; Genentech; Gilead Sciences; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Pfizer; Progenics
 
Felix Y Feng
Stock and Other Ownership Interests - Artera; Bluestar Genomics; Serimmune
Consulting or Advisory Role - Artera; Astellas Pharma; Bayer; BlueStar Genomics; Bristol Myers Squibb; Bristol Myers Squibb (BMS); Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; POINT Biopharma; Roivant; SerImmune; Tempus; Varian Medical Systems
Research Funding - Zenith Epigenetics
 
William U. Shipley
No Relationships to Disclose
 
Jeff Simko
No Relationships to Disclose
 
Kent William Mouw
Stock and Other Ownership Interests - Riva Therapeutics
Honoraria - OncLive/MJH Life Sciences; UpToDate
Consulting or Advisory Role - Riva Therapeutics; Urogen pharma
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Institutional patent filed on mutational signatures of DNA repair deficiency
 
David Tomoaki Miyamoto
Research Funding - Cardiff Oncology (Inst)
 
Alan Pollack
No Relationships to Disclose
 
Dror Dror Michaelson
Employment - Cullinan Oncology (I)
Stock and Other Ownership Interests - Cullinan Oncology (I); Jounce Therapeutics (I)
Honoraria - Eisai; Exelixis; Janssen Oncology; Merck; Pfizer
Consulting or Advisory Role - Eisai; Exelixis; Janssen Oncology; Merck
Research Funding - Bristol Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
Expert Testimony - Bayer; EI Dupont
 
Anthony L. Zietman
Leadership - Elsevier
 
John Coen
No Relationships to Disclose
 
Douglas M. Dahl
No Relationships to Disclose
 
Ashesh B. Jani
No Relationships to Disclose
 
Luis Souhami
No Relationships to Disclose
 
Brian K. Chang
No Relationships to Disclose
 
R. Jeffrey Lee
No Relationships to Disclose
 
Stephanie L. Pugh
No Relationships to Disclose
 
Phuoc T. Tran
Honoraria - Reflexion Medical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Health; Dendreon; GenomeDx; Janssen; Myovant Sciences; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
Travel, Accommodations, Expenses - Reflexion Medical